Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Capital Expenditures (2016 - 2025)

Corcept Therapeutics' Capital Expenditures history spans 10 years, with the latest figure at $50000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 58.68% year-over-year to $50000.0; the TTM value through Dec 2025 reached $211000.0, down 90.29%, while the annual FY2025 figure was $211000.0, 90.29% down from the prior year.
  • Capital Expenditures for Q4 2025 was $50000.0 at Corcept Therapeutics, down from $57000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.6 million in Q3 2024 and bottomed at $12000.0 in Q1 2022.
  • The 5-year median for Capital Expenditures is $103000.0 (2023), against an average of $212750.0.
  • The largest annual shift saw Capital Expenditures tumbled 90.48% in 2022 before it skyrocketed 4318.92% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $65000.0 in 2021, then tumbled by 52.31% to $31000.0 in 2022, then increased by 19.35% to $37000.0 in 2023, then soared by 227.03% to $121000.0 in 2024, then crashed by 58.68% to $50000.0 in 2025.
  • Per Business Quant, the three most recent readings for CORT's Capital Expenditures are $50000.0 (Q4 2025), $57000.0 (Q2 2025), and $104000.0 (Q1 2025).